Igenica Biotherapeutics (immune oncology asset)

Business Data, Corporate Office and Headquarter Address

About

Igenica Biotherapeutics (immune oncology asset) is Buildings and Property in United States that focus on a portfolio business. They cover business area such as a portfolio, immune oncology therapy asset, immunotherapy, immunological control point, resistance, patient, cancer.

Business Type

Buildings and Property

Country

United States

Founded

-

Company Focus

A Portfolio

Website

-

Corporate Office and Headquarter Office address:

863A Mitten Road.
Suite 100B2
Burlingame, CA 94010
United States

Phone number:

Private

Office Opening Hours*:

Monday 9.30 - 17.00
Tuesday 9.30 - 17.00
Wednesday 9.30 - 17.00
Thursday 9.30 - 17.00
Friday 9.30 - 17.00
Saturday Closed
Sunday Closed

Business Coverage

a portfolioimmune oncology therapy assetimmunotherapyimmunological control pointresistancepatientcancer

* We use standard office opening hours in near Igenica Biotherapeutics (immune oncology asset)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.

Igenica Biotherapeutics (immune oncology asset) Frequently Asked Questions

What or who is Igenica Biotherapeutics (immune oncology asset)?

Igenica Biotherapeutics (immune Oncology Asset) is Buildings and Property business from United States that founded in - ( years old in ), Igenica Biotherapeutics (immune oncology asset) business is focusing on A Portfolio.

Where is Igenica Biotherapeutics (immune oncology asset) headquarter and corporate office address?

Igenica Biotherapeutics (immune oncology asset) headquarter office and corporate office address is located in 863A Mitten Road. Suite 100B2 Burlingame, CA 94010 United States.

Where is Igenica Biotherapeutics (immune oncology asset) country origins?

Igenica Biotherapeutics (immune oncology asset) was founded in United States.

What is A Portfolio business focus on?

In , Igenica Biotherapeutics (immune oncology asset) is currently focus on a portfolio sector.

Disclaimer: This website is not affiliated with Igenica Biotherapeutics (immune oncology asset), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.